Cardiology/Vascular Diseases | Phase I Developments

Gesynta Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Orexo's Partner Gesynta Pharma Announces Positive Results from Phase 1 Study for OX-MPI

Lead Product(s): BI1029539

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 15, 2020

Details:

The clinical study was aimed at evaluating the safety, tolerability, pharmacokinetic and pharmacodynamic properties of OX-MPI to healthy subjects after single and multiple ascending dosages.

Silence Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Silence Therapeutics Announces Collaboration with AstraZeneca to Discover and Develop siRNA Therapeutics

Lead Product(s): Small interfering RNA

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: AstraZeneca PLC

Deal Size: $2,080.0 million Upfront Cash: $60.0 million

Deal Type: Collaboration March 26, 2020

Details:

Companies working together to deliver siRNA molecules to liver, breast, lung and other tissues. Within the first three years of the agreement the parties anticipate starting work on five targets.

Heartseed

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Heartseed and ITOCHU CHEMICAL FRONTIER Sign Capital Alliance Agreement

Lead Product(s): Allogeneic iPSC-derived cardiomyocytes

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Itochu Chemical Frontier

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement March 10, 2020

Details:

Through this partnership, Heartseed will leverage ICF’s global network of academia and research institutions to explore iPS-Cell and Cardiomyocyte-related business opportunities.

Grindeks AS

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

LATVIA Latvia

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Grindeks has successfully completed the Phase 1 Clinical Study of Its New Investigational Medicinal Product Methyl-GBB

Lead Product(s): Methyl-GBB

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 05, 2020

Details:

Preclinical studies have demonstrated the efficacy of the new molecule in reducing heart infarct size as a result of mitochondrial protection and attenuation of atherosclerosis progression.

Cytokinetics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Cytokinetics Announces Preclinical Data For AMG 594 Presented At The Keystone Symposium On Heart Failure.

Lead Product(s): AMG 594

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 03, 2020

Details:

In vitro studies demonstrate cardiac troponin activator selectively activates cardiac muscle fibers with little effect on slow skeletal muscle or fast skeletal muscle.

HUYA Bioscience International

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

HUYA Bioscience International® Announces the Successful Completion of Phase 1 Trial of HBI-3000

Lead Product(s): Sulcardine sulfate

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 28, 2020

Details:

Phase 2 trial will test the unique multi-channel ion blocker in acute atrial fibrillation.

Neurimmune

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Neurimmune Announces the Initiation of a Phase 1 Study of NI006 for the Treatment of ATTR Cardiomyopathy

Lead Product(s): NI006

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 27, 2020

Details:

Phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetics and exploratory efficacy of NI006 in patients with wild-type and hereditary forms of ATTR cardiomyopathy.

Arrowhead Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Arrowhead Reports Interim Clinical Data on ARO-APOC3 and ARO-ANG3

Lead Product(s): ARO-APOC3

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 05, 2020

Details:

Multiple-dose data across various patient populations show marked improvement in multiple lipid parameters.

Asklepios BioPharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

AskBio Reveals First Patient Dosed in Phase 1 AAV Gene Therapy Trial

Lead Product(s): NAN-101

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 04, 2020

Details:

AskBio dosed first patient in a Phase 1 clinical trial of NAN-101. The aim of the study is to identify potential therapeutic targets to restore heart function.

Cardior Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Cardior Pharmaceuticals Demonstrates Reversal of Heart Failure with Lead Compound CDR132L

Lead Product(s): CDR132L

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 31, 2020

Details:

In the in vivo study, Cardior´s compound CDR132L effectively prevented maladaptive growth and remodeling and restored cardiac function in a dose-dependent manner.

Find

Find Drugs for Cardiology/Vascular Diseases in Phase I Clinical Development

Phase I

Product Type

Companies

Gesynta Pharma

Orexo's Partner Gesynta Pharma Announces Positive Results from Phase 1 Study for OX-MPI

Silence Therapeutics

Silence Therapeutics Announces Collaboration with AstraZeneca to Discover and Develop siRNA Therapeutics

Heartseed

Heartseed and ITOCHU CHEMICAL FRONTIER Sign Capital Alliance Agreement

Grindeks AS

Grindeks has successfully completed the Phase 1 Clinical Study of Its New Investigational Medicinal Product Methyl-GBB

Cytokinetics

Cytokinetics Announces Preclinical Data For AMG 594 Presented At The Keystone Symposium On Heart Failure.

HUYA Bioscience International

HUYA Bioscience International® Announces the Successful Completion of Phase 1 Trial of HBI-3000

Neurimmune

Neurimmune Announces the Initiation of a Phase 1 Study of NI006 for the Treatment of ATTR Cardiomyopathy

Arrowhead Pharmaceuticals

Arrowhead Reports Interim Clinical Data on ARO-APOC3 and ARO-ANG3

Asklepios BioPharmaceutical

AskBio Reveals First Patient Dosed in Phase 1 AAV Gene Therapy Trial

Cardior Pharmaceuticals

Cardior Pharmaceuticals Demonstrates Reversal of Heart Failure with Lead Compound CDR132L